MML Investors Services LLC Sells 6,047 Shares of Amgen Inc. (NASDAQ:AMGN)

MML Investors Services LLC lessened its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 3.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 186,366 shares of the medical research company's stock after selling 6,047 shares during the period. MML Investors Services LLC's holdings in Amgen were worth $48,574,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also made changes to their positions in the company. Centricity Wealth Management LLC acquired a new stake in shares of Amgen in the 4th quarter valued at approximately $25,000. Ritter Daniher Financial Advisory LLC DE boosted its position in Amgen by 66.2% in the fourth quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock valued at $33,000 after buying an additional 51 shares in the last quarter. Synergy Investment Management LLC bought a new stake in shares of Amgen during the fourth quarter worth $34,000. Atala Financial Inc acquired a new position in shares of Amgen during the fourth quarter worth $34,000. Finally, Heck Capital Advisors LLC bought a new position in shares of Amgen in the 4th quarter valued at $36,000. Institutional investors and hedge funds own 76.50% of the company's stock.

Amgen Stock Up 0.4 %

Shares of NASDAQ AMGN traded up $1.00 during midday trading on Friday, hitting $280.84. 1,994,531 shares of the stock traded hands, compared to its average volume of 2,790,190. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85. The business has a 50 day moving average price of $301.52 and a two-hundred day moving average price of $292.83. The company has a market cap of $150.99 billion, a PE ratio of 37.20, a P/E/G ratio of 2.63 and a beta of 0.59.

Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. On average, equities analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be issued a $2.38 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.39%. Amgen's dividend payout ratio is presently 126.09%.

Insider Activity

In other Amgen news, EVP David M. Reese sold 25,225 shares of Amgen stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the transaction, the executive vice president now owns 36,922 shares of the company's stock, valued at $11,240,533.68. This trade represents a 40.59 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Nancy A. Grygiel sold 1,589 shares of the company's stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the completion of the transaction, the senior vice president now directly owns 7,210 shares of the company's stock, valued at approximately $2,195,228.70. This represents a 18.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 69,341 shares of company stock worth $20,644,335 over the last 90 days. 0.69% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

AMGN has been the subject of a number of recent research reports. Citigroup reaffirmed a "neutral" rating on shares of Amgen in a report on Wednesday, February 5th. Johnson Rice set a $294.00 price objective on Amgen in a research note on Wednesday, March 5th. Morgan Stanley lifted their target price on shares of Amgen from $328.00 to $330.00 and gave the stock an "equal weight" rating in a research report on Wednesday, April 9th. Bank of America upped their price target on shares of Amgen from $275.00 to $294.00 and gave the company an "underperform" rating in a research report on Wednesday, March 5th. Finally, Piper Sandler Companies reiterated an "overweight" rating and set a $310.00 price target on shares of Amgen in a report on Thursday, January 2nd. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $310.57.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.